Biography

Dr. Maria Beumont is Vice President and Chief Medical Officer at TB Alliance, where she leads clinical strategy and oversees clinical trials for new TB treatments. She joined in 2022 with over 20 years of pharmaceutical development experience, including key roles at Janssen and Chiron. At Janssen, she advanced therapies for hepatitis C and led the Hepatitis Franchise. Earlier, she directed HIV Services for the City of Philadelphia. Dr. Beumont earned her MD from the University of Buenos Aires and completed her Internal Medicine residency at Abington Memorial Hospital and an Infectious Diseases fellowship at the University of Pennsylvania.

Expertise

TB Diagnostics
Public Health

Key Impacts

Pretomanid exposure is not increased by severely impaired renal function

Based on the PK results, the study monitoring committee concluded there was no need to proceed to Part B of the study. In conclusion, renal impairment does not increase pretomanid exposure.1 This work was supported by the Division of Microbiology and Infectious Diseases at the National Institutes of Health under contracts HHSN272201300021I and 75N93022D00018.

Source: Conference 2024

Research Summaries

PAPER
New analysis compares liver safety of TB regimens
23 Mar 2025